Blood
Articles in this Issue
Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups
Abstract Introduction The BIG-1 multicenter study was a prospective trial designed for younger AML patients with multiple randomizations at...
Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers
Abstract Introduction Stem cell collection after 4–8 cycles of induction therapy remains standard for multiple myeloma (MM), supporting auto...
Pulmonary function tests performed prior to CAR-T cell administration could be instrumental in predicting post-treatment pulmonary toxicity: A single-arm prospective study
Abstract Introduction: Chimeric antigen receptor T (CAR-T) cells, a novel anticancer treatment introduced less than a decade ago, have demon...
Less is more: Improving outcomes in haemato-oncology with optimal antibiotic use for febrile neutropenia
Abstract Background: Fluoroquinolone (FQ) prophylaxis for febrile neutropenia (FN) is supported by international guideli...
No increase in incidence of central nervous system (CNS) relapse after removal of cns prophylaxis in large B cell lymphoma: A real-world retrospective study.
Abstract The publication of studies demonstrating significant uncertainty in the efficacy of central nervous system (CNS) prophylaxis in lar...
SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer
Abstract Introduction. Chimeric antigen receptor (CAR) T therapy is now used in second and later lines of treatment in patients with B-cell l...
Randomized controlled trial-in-progress of an interdisciplinary treatment program for youth with chronic SCD pain: Integrative strong body and mind training for sickle cell disease (I-STRONG)
Abstract Background and Significance: Up to 20% of adolescents living with sickle cell disease (SCD) experience chronic pain (pain on most d...
Novel DKK1-A2 CAR-T cell therpy for hematologic malignancies
Abstract Background DKK1 (Dickkopf-1) is a secreted protein that acts as an antagonist of the Wnt/β-catenin signaling pathway. DKK1 overexpr...
Ruxolitinib in malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH): A systematic literature review
Abstract Introduction: HLH (Hemophagocytic lymphohistiocytosis) is a critical hyperinflammatory syndrome caused activation of cytotoxic T-ce...
Factors associated with clinically significant systemic methotrexate absorption following intrathecal methotrexate administration - a prospective Study
Abstract Intrathecal methotrexate (IT MTX) is a widely used treatment modality for the treatment of hematological malignancies, both as a th...
Full assessment of clinical transfusion support (FACTS): A prospective Study to determine the burden of sickle cell anemia on pediatric blood transfusion use in a malaria-endemic region in Africa
Abstract Introduction: Half of all blood transfusions in Africa are administered to children. The World Health Organization attributes this...
Relapse associated aberrant DNA hypermethylation in AML post-allogeneic stem cell transplantation
Abstract Introduction Allogeneic stem cell transplantation (SCT) remains a cornerstone of curative therapy for acute mye...
Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes
Abstract Introduction: In November 2021 ropeginterferon alpha-2B (ropeg) was approved by the FDA for front-line management of PV regardless...
Dosing patterns of ponatinib in patients with chronic-Phase chronic myeloid leukemia and effect on treatment: Analysis of specialty pharmacy data in the United States
Abstract Introduction Ponatinib, the only BCR::ABL1 TKI with no contraindicated mutations, has been evaluated in patients (pts) with chronic...
BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study
Abstract Background Multiple myeloma (MM) is the second most common hematologic malignancy. In recent years, the introduction of several nov...
Trends in sepsis and multiple myeloma-related mortality among adults in the United States from 1999 to 2020
Abstract Introduction Immune dysregulation is a hallmark of multiple myeloma (MM), characterized by impaired humoral immunity and increased...
17p cytogenetic changes in TP53-mutated AML
Abstract Background In acute myeloid leukemia (AML), chromosomal rearrangements and point mutations involving the tumor suppressor gene TP53...
Outcomes of concomitant Philadelphia chromosome-positive and CRLF2-rearranged B-cell ALL
Abstract Background: Ph-like acute lymphoblastic leukemia (Ph-like ALL) represents a high-risk subgroup of B-cell ALL with a very high rate...
Real world outcomes of patients with cold agglutinin disease
Abstract Background: Cold agglutinin disease (CAD) is a rare clonal IgM disorder of haemolysis by antibodies that bind to I/i red cell antig...
Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study
Abstract Background: Super-elderly patients (≥80 years) with Diffuse Large B-cell Lymphoma (DLBCL) represent a significant therapeutic chall...
Patient-derived monoclonal anti-HPA-1a can induce platetet activation through fcyriia
Abstract Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a pregnancy-associated disorder caused by maternal alloantibodies targeti...
Impact of interhospital transfer on inpatient outcomes in Acute Myeloid Leukemia
Abstract Background: Acute myeloid leukemia (AML) frequently requires urgent inpatient management, and interhospital transfers may delay def...
Bi-specific T-cell engagers as a bridge to ciltacabtagene autoleucel in Relapsed/Refractory multiple myeloma: Real-world outcomes in an underserved urban population
Abstract Introduction Patients with relapsed/refractory multiple myeloma (RRMM) face limited treatment options and poor outcomes, with media...
The transition from CHIP to overt myeloproliferative neoplasms: A 13-year longitudinal study of JAK2 positive citizens
Abstract Background: Clonal hematopoiesis is associated with thromboembolic complications as well as an increased risk of progression to hema...
Clinical characteristics and response in olutasidenib-treated Relapsed/Refractory mIDH1 Acute Myeloid Leukemia (AML) patients with stable disease following two treatment cycles
Abstract Background: Olutasidenib is a potent, selective oral inhibitor of mutated IDH1 (mIDH1) approved for the treatment of relapsed or re...